Mucosal healing (MH) represents a crucial factor for maintaining gut homeostasis. Indeed, in inflammatory bowel disease, MH has become the standard therapeutical target, because it is associated with more effective disease control, more frequent steroid-free remission, lower rates of hospitalization and surgery, and improved quality of life. In this scenario, gut microbiota is a crucial player in modulating intestinal repair and regeneration process. It can act on the tumor necrosis factor-α production, modulation of reactive oxygen and nitrogen species, activity of matrix metalloproteinases and on many other mechanisms strictly involved in restoring gut health. In this review, we analyze and review the literature on the role of gut microbiota in sustaining mucosal injury and achieving MH.

1.
Bamias G, et al: New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation. Cytokine 2012;59:451-459.
2.
Xavier RJ, Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-434.
3.
Jostins L, et al: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-124.
4.
Khor B, Gardet A, Xavier RJ: Genetics and pathogenesis of inflammatory bowel disease. Nature 2011;474:307-317.
5.
de Bruyn M, et al: Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease. Inflamm Bowel Dis 2014;20:339-352.
6.
Scaldaferri F, et al: The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol 2012;46(suppl):S12-S17.
7.
Scaldaferri F, et al: Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. Biomed Res Int 2013;2013:435268.
8.
Rogler G, et al: Mucosal healing and deep remission: what does it mean? World J Gastroenterol 2013;19:7552-7560.
9.
Macdonald TT, Monteleone G: Immunity, inflammation, and allergy in the gut. Science 2005;307:1920-1925.
10.
Neurath MF: New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol 2014;7:6-19.
11.
Rieder F, et al: Results of the 2nd scientific workshop of the ECCO (III): basic mechanisms of intestinal healing. J Crohns Colitis 2012;6:373-385.
12.
Maxwell PH, et al: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-275.
13.
Semenza GL: Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 1998;8:588-594.
14.
Giatromanolaki A, et al: Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J Clin Pathol 2003;56:209-213.
15.
Stappenbeck TS, Hooper LV, Gordon JI: Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci U S A 2002;99:15451-15455.
16.
Zocco MA, et al: Bacteroides thetaiotaomicron in the gut: molecular aspects of their interaction. Dig Liver Dis 2007;39:707-712.
17.
Schirbel A, et al: Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis. Gastroenterology 2013;144:613-623.e9.
18.
McKenzie SJ, et al: Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J Clin Invest 1996;98:136-141.
19.
Kruidenier L, et al: Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease. J Pathol 2003;201:7-16.
20.
Sokol H, et al: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008;105:16731-16736.
21.
Sokol H, et al: Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009;15:1183-1189.
22.
Darfeuille-Michaud A, et al: High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004;127:412-421.
23.
Baumgart M, et al: Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J 2007;1:403-418.
24.
Kotlowski R, et al: High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 2007;56:669-675.
25.
Lupp C, et al: Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2007;2:204.
26.
Naser SA, et al: Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet 2004;364:1039-1044.
27.
Rigottier-Gois L: Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis. ISME J 2013;7:1256-1261.
28.
Hooper LV, et al: Host-microbial symbiosis in the mammalian intestine: exploring an internal ecosystem. Bioessays 1998;20:336-343.
29.
Kumar A, et al: Commensal bacteria modulate cullin-dependent signaling via generation of reactive oxygen species. EMBO J 2007;26:4457-4466.
30.
Kumar A, et al: The bacterial fermentation product butyrate influences epithelial signaling via reactive oxygen species-mediated changes in cullin-1 neddylation. J Immunol 2009;182:538-546.
31.
Cerignoli F, et al: Regulation of MAP kinases by the VHR dual-specific phosphatase: implications for cell growth and differentiation. Cell Cycle 2006;5:2210-2215.
32.
Wentworth CC, et al: Enteric commensal bacteria induce extracellular signal-regulated kinase pathway signaling via formyl peptide receptor-dependent redox modulation of dual specific phosphatase 3. J Biol Chem 2011;286:38448-38455.
33.
Baugh MD, et al: Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999;117:814-822.
34.
Laukoetter MG, Nava P, Nusrat A: Role of the intestinal barrier in inflammatory bowel disease. World J Gastroenterol 2008;14:401-407.
35.
McGuckin MA, et al: Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 2009;15:100-113.
36.
Viswanathan VK, et al: Comparative analysis of EspF from enteropathogenic and enterohemorrhagic Escherichia coli in alteration of epithelial barrier function. Infect Immun 2004;72:3218-3227.
37.
Amieva MR, et al: Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science 2003;300:1430-1434.
38.
Babbin BA, et al: The bacterial virulence factor lymphostatin compromises intestinal epithelial barrier function by modulating rho GTPases. Am J Pathol 2009;174:1347-1357.
39.
Li Q, et al: Invasion of enteropathogenic Escherichia coli into host cells through epithelial tight junctions. FEBS J 2008;275:6022-6032.
40.
Jepson MA, Schlecht HB, Collares-Buzato CB: Localization of dysfunctional tight junctions in Salmonella enterica serovar typhimurium-infected epithelial layers. Infect Immun 2000;68:7202-7208.
41.
Sakaguchi T, et al: Shigella flexneri regulates tight junction-associated proteins in human intestinal epithelial cells. Cell Microbiol 2002;4:367-381.
42.
Chen ML, et al: Disruption of tight junctions and induction of proinflammatory cytokine responses in colonic epithelial cells by Campylobacter jejuni. Infect Immun 2006;74:6581-6589.
43.
Phan QT, et al: Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol 2007;5:e64.
44.
Moreno-Ruiz E, et al: Candida albicans internalization by host cells is mediated by a clathrin-dependent mechanism. Cell Microbiol 2009;11:1179-1189.
45.
Wu S, et al: Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and gamma-secretase-dependent E-cadherin cleavage. J Cell Sci 2007;120(pt 11):1944-1952.
46.
Steck N, et al: Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. Gastroenterology 2011;141:959-971.
47.
Comito D, Cascio A, Romano C: Microbiota biodiversity in inflammatory bowel disease. Ital J Pediatr 2014;40:32.
48.
Zhan Y, et al: Gut microbiota protects against gastrointestinal tumorigenesis caused by epithelial injury. Cancer Res 2013;73:7199-7210.
49.
Pull SL, et al: Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci U S A 2005;102:99-104.
50.
Rakoff-Nahoum S, et al: Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118:229-241.
51.
Swanson PA 2nd, et al: Enteric commensal bacteria potentiate epithelial restitution via reactive oxygen species-mediated inactivation of focal adhesion kinase phosphatases. Proc Natl Acad Sci U S A 2011;108:8803-8808.
52.
Guilloteau P, et al: From the gut to the peripheral tissues: the multiple effects of butyrate. Nutr Res Rev 2010;23:366-384.
53.
Lewis K, et al: Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate. Inflamm Bowel Dis 2010;16:1138-1148.
54.
Ukena SN, et al: Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2007;2:e1308.
55.
Wang H, et al: Escherichia coli Nissle 1917-derived factors reduce cell death and late apoptosis and increase transepithelial electrical resistance in a model of 5-fluorouracil-induced intestinal epithelial cell damage. Cancer Biol Ther 2014;15:560-569.
56.
Donato KA, et al: Lactobacillus rhamnosus GG attenuates interferon-{gamma} and tumour necrosis factor-alpha-induced barrier dysfunction and pro-inflammatory signalling. Microbiology 2010;156(pt 11):3288-3297.
57.
Patel RM, et al: Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function. Am J Pathol 2012;180:626-635.
58.
Orlando A, et al: Lactobacillus GG restoration of the gliadin-induced epithelial barrier disruption: the role of cellular polyamines. BMC Microbiol 2014;14:19.
59.
Yan F, et al: Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007;132:562-575.
60.
Wang L, et al: Activation of epidermal growth factor receptor mediates mucin production stimulated by p40, a Lactobacillus rhamnosus GG-derived protein. J Biol Chem 2014;289:20234-20244.
61.
Carlsson AH, et al: Faecalibacterium prausnitzii supernatant improves intestinal barrier function in mice DSS colitis. Scand J Gastroenterol 2013;48:1136-1144.
62.
Wrzosek L, et al: Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC Biol 2013;11:61.
63.
Dai C, Zhao DH, Jiang M: VSL#3 probiotics regulate the intestinal epithelial barrier in vivo and in vitro via the p38 and ERK signaling pathways. Int J Mol Med 2012;29:202-208.
64.
Czerucka D, et al: Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun 2000;68:5998-6004.
65.
Thomas S, et al: Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol 2011;301:G1083-G1092.
66.
Percival SL, Thomas JG, Williams DW: Biofilms and bacterial imbalances in chronic wounds: anti-Koch. Int Wound J 2010;7:169-175.
67.
Goldsmith JR, Sartor RB: The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. J Gastroenterol 2014;49:785-798.
68.
Garg SK, Croft AM, Bager P: Helminth therapy (worms) for induction of remission in inflammatory bowel disease. Cochrane Database Syst Rev 2014;1:CD009400.
69.
Hamady ZZ, et al: Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus. Gut 2010;59:461-469.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.